Promising avenues of therapeutics for bipolar illness by Post, Robert M.
here are multiple promising areas of clinical
therapeutics in the long-term treatment of bipolar dis-
order. Several opportunities are readily at hand, and
only require the necessary academic commitment and
resources to be initiated and completed.For example,a
variety of single-nucleotide polymorphism (SNP) mark-
ers are available for assessing both vulnerability to ill-
ness onset and also treatment response.Combining such
a profile of 50 to 100 SNP markers with clinical attrib-
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Basic scientific advances in understanding the neuropsychobiology of bipolar disorder have given us a multitude of
opportunities to explore and exploit new avenues of therapeutics. Pharmacotherapeutic approaches include: neu-
ropeptides (agonists such as thyrotropin-releasing hormone and antagonists such as corticotropin-releasing hormone),
neurotrophic factors (especially brain-derived neurotrophic factor), and glutamatergic mechanisms (such as riluzole,
ketamine, and antagonists of the NR-2B subunit of the glutamate receptor). Physiological interventions that would
offer alternatives to electroconvulsive therapy include: repeated transcranial magnetic stimulation, especially at more
intense stimulation parameters; magnetic stimulation therapy (seizures induced more focally by magnetic rather than
electrical stimulation with resulting reduced meaning loss); vagal nerve stimulation, and deep brain stimulation.
However, these, as well as the panoply of existing treatments, require further intensive investigation to place each of
them in the proper therapeutic sequence and combination for the individual patient, based on development of bet-
ter clinical and biological predictors of response. Large clinical trial networks and development of systematic research
in clinical practice settings, such as that featured by the National Cancer Institute for cancer chemotherapy, would
greatly accelerate the progress in incorporating new, as well as existing, agents into the best treatment strategies. The
bipolar disorders, which are increasingly recognized as complex, highly comorbid conditions with a high morbidity
and mortality, of which the majority start in childhood and adolescence, are not likely to respond completely to any
single new treatment agent, and new public health initiatives and research strategies are needed as much as any new
single treatment advance.      
© 2008, LLS SAS Dialogues Clin Neurosci. 2008;10:193-201.to be able to treat the illness much earlier than is com-
monly accomplished now, and even consider the possi-
bility of primary prophylaxis for those at the highest risk.
Currently, it is very much a clinician’s best guess and a
hit-or-miss proposition in assigning the optimal mood
stabilizer or mood stabilizer combination for those with
a definite diagnosis.If one were able to utilize this com-
bination of SNP and other markers to more rationally
assign appropriate drugs to individual patients, one
might be able to ward off the very considerable mor-
bidity and mortality associated with the early phases of
the disorder,when multiple severe recurrences are com-
mon,both before and after treatment is initiated.
This is a particularly critical issue for children and ado-
lescents with early-onset bipolar illness which, paren-
thetically,comprises some 55% to 60% of all bipolar ill-
ness in adults.
1-3These individuals with early onsets have
the longest delays to first treatment and a more severe
course of illness throughout their lives into adulthood,
both as measured retrospectively and confirmed
prospectively.Thus, it would appear imperative to treat
these patients early and effectively in an attempt to
avoid this otherwise poor prognosis.What the best treat-
ments are for childhood bipolar illness is just beginning
to be defined,
4 and major new initiatives are needed,
including the formation of treatment outcome networks
to better define both optimal treatment and prediction




Neuropeptides may provide optimal targets for thera-
peutics of the affective disorders in light of their longer
time frame of activity and behavioral modulation com-
pared with classical neurotransmitters. A number of
companies are attempting to develop corticotropin-
releasing hormone (CRH) antagonists with the hope
that these will be useful in depression and anxiety syn-
dromes.Conversely,some neuropeptides are thought to
be potentially endogenous antidepressant or mood-sta-
bilizing substances,with thyrotropin-releasing hormone
(TRH) being a critical example.
5-10Thus,novel targets of
drug development may be derived both from inhibition
of primary pathological mechanisms, such as CRH, but
also potentially enhancing endogenous secondary com-
pensatory processes,such as TRH.
11,12
Neurotrophic factors 
Brain-derived neurotrophic factor (BDNF) has been
implicated in the genetic and environmental vulnerabil-
ity to bipolar onset,episode occurrence,and progression,
and in many of the acute and long-term treatments of
the illness.
13 BDNF is also positive in many models of
depression,and this raises the possibility of more imme-
diate antidepressant effects being achieved by direct
manipulation of BDNF, potentially with an intrathecal
route of administration
9 in order to circumvent the
blood-brain-barrier.
At the same time, BDNF increases in the ventral
tegmental-nucleus accumbens-dopaminergic pathway
appear critical to the manifestations of both defeat stress
behavior and cocaine-induced behavioral sensitization.
14
There are very prominent learned components in both
the manifestation of defeat stress behaviors and
increased activation and responsivity to repeated doses
of cocaine.Since BDNF appears to be intimately impli-
cated in these learned associations, as it is necessary to
the occurrence of long-term potentiation and long-term
memory,ways of altering the substrates conveying these
learned behaviors and deconditioning them might prove
salutary.
Moreover, chronic cocaine administration in animals
and in man increases both brain dynorphin and its sigma
opiate receptor, thus accounting for some of the dys-
phorogenic and psychotomimetic effects of chronic
cocaine administration that are not apparent on initial
applications. Suppressing these overpotentiated dynor-
phinergic mechanisms thus could be a target of thera-
peutics, but at present it is not at all obvious how this
might be accomplished. Sigma opiate antagonists may
hold some promise for initial success, but would likely
ultimately be associated with increases in sigma opiate
receptor sensitivity,which could be counterproductive.
One potential way of attempting to rebalance neural
substrates associated with increased psychopathological
behavior would be to combine pharmacotherapy with
neurostimulatory techniques. Another approach pio-
neered by Kalivas
15 is to reduce glutamate secretion in
the nucleus accumbens that is associated with cue and
stress-induced relapse in cocaine-abstinent animals.This
can be accomplished with the glutathione precursor N-
acetyl cysteine which acts on the cysteine-glutamate
exchanger,and now has preliminary evidence of efficacy
in animals and humans.
Pharmacological aspects
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the affective disorders
Electroconvulsive therapy (ECT) has been used as a
major therapeutic modality for depression and the affec-
tive psychoses for more than half a century.While highly
acutely effective,recent data suggest that its long-term effi-
cacy on mood stability is quite low,with only some 20% or
less of acutely-treated patients remaining remitted at 6
months,whether or not they received continuation (pro-
phylactic) ECT treatment.
16 Moreover, Sackeim et al
17
have demonstrated that the degree of deficit in autobio-
graphical memory is directly proportional to the number
of bilateral ECT treatments.These concerns about mem-
ory loss further complicate the procedure,which has a con-
siderable stigma based on the necessity of inducing a
seizure,even under anesthesia and muscle paralysis,as per-
formed at the present time.
Repeated transcranial magnetic stimulation (rTMS) of the
brain may ultimately be able to replace ECT for a sub-
group of patients; five of six studies revealed that both
treatments showed equal efficacy in a small series of
patients,with rTMS showing no cognitive dysfunction.
18
However, what remains to be better delineated is the
nature of the continuation and prophylactic management
of acutely responsive patients to rTMS.The FDA is cur-
rently considering approval of one piece of equipment,
19
and we look forward to delineation of the optimal para-
meters for individual patients with this technology for
brain stimulation which does not require a seizure or anes-
thesia. Recent data from Mark George (personal com-
munication,26 September 2007) suggest excellent results
in highly treatment-refractory patients with shorter inter-
stimulus intervals generating 6000 to 8000 pulses per daily
session, with 10 Hz over left prefrontal cortex at high
intensity (130% of motor threshold).
As such,rTMS has other potential advantages,including
the possibility of administering it during attempts to
enhance neural circuits associated with positive adapta-
tions (using 20Hz rTMS) and dampen overactive neural
circuits associated with pathological processes and dys-
function (using 1 Hz rTMS).Extinction and decondition-
ing of anxiety disorders has been demonstrated with
adjunctive use of the glutamate enhancer d-cycloserine,
20
and one can similarly envision enhancing,with rTMS,glu-
tamatergic and other neural circuits in the medial pre-
frontal cortex that are involved in new learning, which
appears to be a critical component of habituation or
desensitization.rTMS is also capable of activating BDNF
and other neurotropic factors,and thus holds the possibil-
ity of reprogramming neural circuitry in a relatively
regionally selective fashion during cognitive behavioral
therapy or other psychorehabilitative processes.
Vagal nerve stimulation (VNS) was recently approved for
treatment of refractory depression after initially being
approved as an adjunctive approach to refractory
epilepsy.
21-23While not yet widely endorsed or accepted by
most agencies involved with reimbursement,the fact that
the rate of clinical improvement appears to grow over the
course of a year (in contrast to most treatments which tend
to show a tolerance-like process or loss of effectiveness
over time),suggests that it is likely an active treatment.
Preliminary data from Marangell,Suppes,and colleagues
suggest that VNS may also be useful in mood unstable and
rapid cycling bipolar patients. Further studies of this
modality in bipolar illness are obviously indicated in light
of its promise for long-term management in an illness
where the primary therapeutic target is prevention of
recurrences.
Deep-brain stimulation (DBS) is a widely accepted pro-
cedure for patients with some types of refractory parkin-
sonism, and data are just beginning to be accumulated
about efficacy in the mood disorders. Initially, highly
promising improvement in patients with refractory depres-
sion has been accomplished by Mayberg and colleagues
24
with stimulation of area 25 in the anterior cingulate gyrus.
The specificity of therapeutic effects to this location and
the optimal parameters again require considerable further
study and evaluation.
Over many decades,Russians teams have claimed thera-
peutic effects of low-level DC (direct current) stimulation.
A series of studies suggest the promise of this procedure,
25-27
as do other approaches to manipulating low-level mag-
netic fields with alterations of the parameters of magnetic
resonance spectroscopic imaging (MRSI).
28 Should rTMS
and these lesser invasive techniques of DC stimulation
and low-level magnetic fields prove useful in preliminary
controlled studies,further intensive study would appear
warranted in light of their convenience and apparent
safety.Studies in animals and man also suggest their util-
ity in enhancing pharmacotherapy.
29
Novel mechanism of antidepressant action
Given the ambiguity of antidepressant efficacy in bipo-
lar depression
30 and the risks of switching or cycle accel-
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31,32 one mechanistically new drug looks highly
promising.Agomelatine has a novel set of actions, and
proven antidepressant effects in unipolar depression and
potential high effectiveness in bipolar depression, with
an open study
33 indicating about 80% response rates
rather than the usual 30% to 50% rates with traditional
antidepressants.Agomelatine is a serotonin (5-HT)-2c
antagonist which results in the disinhibition of both
dopamine and norepinephrine release, and is also a
melatonin M1 and M2 receptor agonist.It is also a 5-HT-
2B antagonist,like some other antidepressants and most
atypicals.The 5HT-2C receptor antagonism is thought to
increase slow-wave sleep (SWS).
34,35 Increases in SWS
have now been demonstrated in depressed patients,
36
and the receptor  profile of this new antidepressant
should help sleep onset, cause a phase advance in
patients with circadian phase delays,
37 and synchronize
biological rhythms.
38-41 The drug is also weight-neutral,
and putatively does not involve the sexual dysfunction
common to most selective selective serotonin uptake
inhibitors (SSRIs).Thus, the novel norepinephrine and
dopamine disinhibition (NDDI), combined with mela-
tonin receptor agonism and circadian phase realignment,
offer potential therapeutic approaches to bipolar depres-
sion.
Altered glutamatergic mechanisms: the potential for
acute onset of antidepressant effects
While most of our efficacious antidepressant treatments
have typically required 2 to 4 weeks or longer for maxi-
mal therapeutic effectiveness,many different procedures
indicate that results can be achieved much more rapidly.
In the approximate 50% of responders to one night of
sleep deprivation, therapeutic effects are apparent (lit-
erally) overnight.The critical issue is maintaining effi-
cacy, and several attempts have shown to be effective




44 As noted above, the antidepressant
effects of TRH are also rapid in onset, but the brief
duration again limits current utility.
Intravenous administration of the glutamate antagonist
ketamine also appears capable of inducing rapid onset
of antidepressant effects and in this case, improvement
can last some 3 to 5 days or longer.
45 How to capture the
acute onset of effects in the long term remains a thera-
peutic conundrum.One approach to this being explored
is to follow ketamine administration with another glu-
tamate-active agent, riluzole, which has shown promise
in the treatment of unipolar and bipolar depressed
patients.
46 This glutamate-active agent is approved for
neural protection in amyotrophic lateral sclerosis, and
both the acute effects of ketamine and longer-term
responses to riluzole demonstrate the potential thera-
peutic utility of altering glutamatergic tone as a novel
approach to therapeutics. In an initial series of three
highly treatment-refractory depressed patients,Charney
et al
47 reported remarkable and sustained effects of acute
ketamine achieved by an additional three intermittent
ketamine infusions.These data suggest a shift in thera-
peutic approaches toward exploring new ways of main-
taining the acute onset of antidepressants induced by
ketamine and related agents. For example, Preskorn et
al
48 reported rapid onset of antidepressant effects with a
specific antagonist of glutamate GluR 2B subunits.
The aminergic systems have proven to be effective tar-
gets of delayed onset of maximum antidepressant
effects, and γ-aminobutyric acid (GABA)ergic mecha-
nisms have been intimately implicated in anxiolytic, if
not antidepressant, efficacy. Whether glutamatergic/
GABAergic balance can be altered from the perspective
of dampening overactive glutamatergic systems remains
to be further explored. It is noteworthy, however, that
Hough and colleagues
49 have demonstrated that the
mood stabilizers lithium,valproate,carbamazepine,and
lamotrigine are all weak inhibitors of calcium influx
through the glutamate N-methyl-D-aspartic acid
(NMDA) receptor, further suggesting that modulation
of this major excitatory neurotransmitter system in brain
through other approaches could prove clinically useful
for patients with bipolar disorder.
To the extent that the ostensibly opposing behaviors and
symptomatology exhibited in depression versus mania
are attributable to excess activity in either inhibitory or
excitatory neural substrates, one could envision how
dampening neural excitability could be of potential use
in both phases of the illness.Among the anticonvulsants,
the sodium-channel blockers, which inhibit glutamate
release, appear to be among those best demonstrating
antimanic efficacy compared with agents which enhance
GABAergic mechanisms (gabapentin,tiagabine,topira-
mate) which, with the exception of valproate, do not
appear to exhibit acute antimanic efficacy.Thus, modu-
lation of glutamate mechanisms both to dampen overex-
citability in both depression and mania,and potentially
enhance glutamatergic tone for new learning and decon-
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approaches to the therapeutics of bipolar disorder.
Considerable evidence implicates alteration in cytokine
levels and functioning in the affective disorders.
50,51
Preliminary attempts at using anti-inflammatory
approaches, such as with antagonists of tumor necrosis
factor, have been successful, and suggest a whole new
approach to therapeutics in the future.
Decreases in BDNF and increases in oxidative stress
have also been seen during episodes of both mania and
depression.
52 As noted above, N-acetyl cysteine (NAC)
is an antioxidant and a glutathione precursor.Recently,
Harvey et al
53 have shown significant effects of NAC
over placebo in preventing bipolar episodes,particularly
depressive recurrences in a 1-year double-blind study.
As an agent with few side effects and having the major
asset of preventing depressive episodes, this compound
holds considerable therapeutic promise,both in its own
right and as a stalking horse for a new class of therapies.
Also intriguing are the effects of NAC in decreasing
cocaine intake noted above,
15,54 and in reducing patho-
logical gambling,
55 problems not uncommon in patients
with bipolar illness.
Vitamins, fatty acids, and other augmenting agents
Megavitamin therapy has not been proven to be effec-
tive in controlled clinical trials, but specific substances
remain promising.For example,augmentation with folic
acid (1 mg/day) is now widely recommended in refrac-
tory depression,based on a series of positive controlled
trials in unipolar depression
56 and in a small trial for flu-
oxetine augmentation.
57 Moreover,it decreases levels of
homocysteine,which is increased in bipolar patients with
cognitive deficits and in those not recovering between
episodes, as well as those being treated with valproate.
As a major cardiovascular risk factor in an illness with a
significantly increased risk of myocardial infarction and
stroke,perhaps homocysteine should be a routine target
of therapeutics with folate and other approaches.
A mixed, but generally positive, literature supports the
effectiveness of omega-3 fatty acids in the treatment or
prevention of depressive episodes.
58 Even in a negative
study of 6 g of eicosapentaenoic acid (EPA) per day in
bipolar patients, younger patients did better on active
treatment, while older persons did better on placebo.
59
Given the growing recognition of childhood onset bipolar
illness in the US,further study of this safe and generally
well-tolerated strategy would have considerable merit.
Another extremely promising augmentation strategy for
residual depression, fatigue, and poor concentration in
bipolar illness is that of modafinil. Frye et al
60 found
highly significant improvement with modafinil compared
with placebo on these symptom measures, and this was
achieved without an increase rate of switch into mania.
Given the increasing evidence of the inadequacy of tra-
ditional antidepressant augmentation
30 and the risks of
associated switching,
61 modafinil augmentation looks
very promising. Moreover, exploration of its nonstimu-
lant mechanism of action may also provide a new target
of therapeutics.
Agents targeted to the multiple comorbidities of bipo-
lar illness
The typical patient with bipolar illness will have other
Axis I and III comorbidities.Therapeutic approaches to
these symptoms have been largely ignored,as many of
the more common and complicated patients are excluded
from the traditional randomized controlled trials.
Nevertheless,therapies directed at these critical areas of
symptomatology are necessary for long-term remission
and well-being.In contrast to lithium,the anticonvulsant
mood stabilizers, valproate, lamotrigine, and carba-
mazepine,and the atypical antipsychotics are also effec-
tive in many of the anxiety disorder comorbidities and
are useful “two-for-one”medication approaches to both
biphasic mood and anxiety symptoms.
On the other hand, some medications are not effective
antimanic treatments, but may be useful in treating
comorbid disorders. This would include topiramate,
which is likely effective in alcohol and cocaine absti-
nence,migraine prevention,post-traumatic stress disor-
der, bulimia, and weight loss; and gabapentin, which is
effective in social phobia and panic disorders,sleep dis-
turbances, pain syndromes, and alcohol abstinence.
Finding new approaches to the common comorbidities
of bipolar illness, which would not exacerbate primary
mood symptoms,would thus be of considerable clinical
interest and benefit. For example, baclofen and rimon-
abont have been suggested as assisting in cocaine avoid-
ance and weight loss, respectively, but both have been
shown to exacerbate depression, such that these agents
which are effective in the primary comorbid condition
would not appear to have utility in patients with bipolar
disorder.
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While there are a number of useful models for acute
antidepressant and antimanic efficacy, the field suffers
from a lack of models representing biphasic alterations
in mood and behavior, and the inherent cyclicity or
mood phase reversal and recurrence of the disorder.
One of the few exceptions to this is Antelman’s model
of intermittent stressors or cocaine administration,which
appears to be associated with inductions of alterations
in hyperactive and inhibited behavior.
62 Interestingly,in
this model, inositol appears to improve and stabilize
both the behavioral and neurochemical alterations evi-
dent in this model.Examination of the efficacy of inosi-
tol in acute depression has led to equivocal results and
perhaps deserves further exploration as a potential long-
term therapeutic tool.
63,64
One of the more intriguing features of bipolar illness is
its potential for recurrence and behavioral oscillation to
opposite poles at almost any frequency from intermit-
tent and infrequent episodic recurrences to more rapid,
ultrarapid,and even ultradian cycling,wherein mood can
fluctuate numerous times within a single 24-hour period.
Thus,examination of mechanisms involved in this extra-
ordinarily wide range of temporal manifestations of
opposing mood and behavior in bipolar disorders would
be a fruitful avenue of investigation beyond the phe-
nomena that show regular and invariant cyclicity in a
given time domain.Thus, studies of diurnal alterations
in circadian rhythms have been a primary focus of the-
oretical and empirical inquiry directed at therapeutics of
bipolar disorder, but may not be adequate to deal with
the extraordinary variability and aperiodicity that can
be manifest in the illness.The dihydropyridine L-type
calcium channel blocker nimodipine has shown prelim-
inary success in some patients with ultrafast (ultradian)
mood switches,
65 and this class of compounds deserves
further exploration,even though a new dihydropyridine
did not differ from placebo.
Overview
There are obviously a multiplicity of novel potential
approaches to the therapeutics of bipolar illness, as
briefly outlined here.While each requires much further
exploration in order to validate its potential utility,such
exploration is also likely to yield many surprises, and
some approaches will be developed much more rapidly
than we can currently anticipate and envision.We have
only preliminarily dealt with the issue of psychotherapy
in conjunction with other approaches, but emphasize
that there is a rich controlled clinical trial literature
demonstrating the effectiveness of several different
types of psychotherapeutic and psychoeducational
approaches to bipolar illness.
66These too may be further
honed and revised for much more optimal short- and
long-term approaches to the complexities of bipolar ill-
ness in particular.
We look forward to the emergence of many innovative
treatments and surprising developments in the realm of
novel therapeutics,but remain chastened by the experi-
ence to date that research funding in bipolar disorder
lags considerably behind that of the other major mental
disorders. Major new initiatives are needed to begin to
address the complexities of the illness and its multiple
comorbidities in a timely fashion. New powerful treat-
ments only introduced late in the course of illness and
without appropriate integration with other therapeutic
modalities may not fare as well as those more optimally
utilized.
One can hope,as new therapeutic approaches evolve and
come to fruition,that this in itself will accelerate progress
in earlier and more sustained treatment of this illness,and,
in turn help enhance further research funding. ❏
Pharmacological aspects
198Novel treatments for bipolar disorder - Post Dialogues in Clinical Neuroscience - Vol 10 . No.2 . 2008
199
Prometedoras líneas terapéuticas para la
enfermedad bipolar
Los avances de las ciencias básicas en la compren-
sión de la neuropsicobiología del trastorno bipolar
han entregado una multitud de oportunidades
para explorar y explotar nuevas líneas terapéuticas.
Las aproximaciones farmacoterapéuticas incluyen:
neuropéptidos (agonistas como la hormona libera-
dora de tirotropina y antagonistas como la hor-
mona liberadora de corticotropina), factores neu-
rotróficos (especialmente el factor neurotrófico
derivado del cerebro) y mecanismos glutamatérgi-
cos (como riluzole, ketamina y antagonistas de la
subunidad NR-2B del receptor de glutamato). Las
intervenciones fisiológicas que ofrecerían alterna-
tivas a la terapia electroconvulsiva incluyen: esti-
mulación magnética transcraneal repetida, espe-
cialmente con los parámetros de estimulación más
intensos; terapia de estimulación magnética (crisis
convulsivas inducidas focalmente más por estimu-
lación magnética que eléctrica que provoquen una
menor pérdida de conciencia); estimulación del ner-
vio vago y estimulación cerebral profunda. Sin
embargo, todas estas intervenciones como la pano-
plia de tratamientos existentes requieren de futu-
ras investigaciones en profundidad para situar a
cada uno de ellos en la secuencia y combinación
terapéutica adecuada para cada paciente, basán-
dose en el desarrollo de los mejores predictores de
respuesta clínica y biológica. Extensas redes de
ensayos clínicos y el desarrollo de investigación sis-
temática en la práctica clínica, como el que ha
caracterizado al Instituto Nacional del Cáncer para
la quimioterapia del cáncer, podrían acelerar bas-
tante el progreso en la incorporación tanto de nue-
vos agentes como de los ya existentes a mejores
estrategias terapéuticas. Los trastornos bipolares,
que cada vez son más reconocidos como complejos,
con alta comorbilidad, alta morbimortalidad, y cuyo
inicio en la mayoría de los casos ocurre en la niñez
y adolescencia; es probable que no respondan com-
pletamente a nuevos agentes terapéuticos especí-
ficos, y se requiera de nuevas iniciativas de salud
pública y estrategias de investigación tanto como
del avance de nuevos tratamientos individuales.
Voies thérapeutiques prometteuses pour la
maladie bipolaire
Les avancées scientifiques dans la compréhension des
mécanismes neuropsychobiologiques des troubles
bipolaires nous ont offert de nombreuses possibili-
tés d’exploration et d’exploitation de nouvelles voies
thérapeutiques.
Les approches pharmacothérapeutiques compren-
nent : les neuropeptides (agonistes comme la thy-
rotropin-releasing hormone ou TRH, et antago-
nistes comme la corticotropin-releasing hormone
ou CRH), des facteurs neurotrophiques (surtout le
brain-derived neurotrophic factor ou BDNF) et des
mécanismes glutamatergiques (comme le riluzole,
la kétamine et les antagonistes de la sous-unité NR-
2B du récepteur au glutamate). Parmi les alterna-
tives physiologiques susceptibles de remplacer
l’électroconvulsivothérapie, on trouve : la stimula-
tion magnétique transcranienne répétée, surtout à
des paramètres de stimulation intensifs ; le traite-
ment par stimulation magnétique (les crises
induites sont plus localisées avec la stimulation
magnétique qu’avec la stimulation électrique et la
perte mnésique est donc moindre) ; la stimulation
nerveuse vagale et la stimulation cérébrale pro-
fonde. Il faut cependant des études supplémen-
taires sur ces techniques et les traitements existants
afin de trouver pour chaque patient les meilleures
association et séquence thérapeutique en dévelop-
pant de meilleurs facteurs prédictifs de réponses cli-
niques et biologiques. De rapides progrès pour-
raient être faits dans ce domaine sur la base de
grandes études cliniques mises en commun et le
développement d’une recherche systématique en
pratique clinique, comme le fait le National Cancer
Institute pour la chimiothérapie anticancéreuse. Il
est peu probable que les troubles bipolaires, de plus
en plus reconnus comme complexes, très comor-
bides avec une mortalité et une morbidité élevées,
dont la majorité débute pendant l’enfance ou
l’adolescence, répondent complètement à un seul
nouveau médicament ; la recherche et des initia-
tives nouvelles de santé publique sont aussi néces-
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